



PSIVIDA REPORTS ILUVIEN® GRANTED MARKETING AUTHORIZATION IN BELGIUM

Now Approved in 12 Countries Worldwide

WATERTOWN, MA – November 12, 2014 -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This marks the 12th country in which ILUVIEN has been approved for commercialization.

In the EU, ILUVIEN is currently marketed in the U.K. and Germany and is scheduled to launch in Portugal this year. ILUVIEN has marketing approval in 11 EU countries and is pending approval in six others.

ILUVIEN was recently approved in the U.S. for treatment of DME. It is indicated for patients previously treated with a course of corticosteroids who did not have a clinically significant rise in intraocular pressure (IOP). ILUVIEN is expected to be commercially available in the U.S. in early 2015.

“We continue to be pleased with the steady progress ILUVIEN is making gaining marketing approvals in Europe, and, of course, recently in the United States,” said Dr. Paul Ashton, President and CEO of pSivida. “We believe ILUVIEN’s efficacy and three-year duration will make it an attractive treatment option for many DME patients, particularly in the U.S. where it has broader labeling.” pSivida is entitled to 20% of the net profits from sales of ILUVIEN by its licensee on a country-by-country, quarter-by-quarter basis.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases utilizing its core Durasert™ and Tethadur™ platform technology systems. pSivida’s lead product candidate, Medidur™ for treatment of posterior uveitis, is being studied in a pivotal Phase III clinical trial. Medidur uses the same injectable, sustained release micro-insert as pSivida’s lead licensed product, ILUVIEN® for the treatment of DME.

ILUVIEN has been approved in the U.S., is marketed in the U.K. and Germany and has or is pending marketing authorization in 15 other EU countries. pSivida’s other

licensed product, Retisert®, an implant that treats posterior uveitis, is sold in the U.S. pSivida's pre-clinical research is focused on ocular and systemic delivery of biologics and drugs to treat of wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: ability to achieve profitable operations and access to capital; fluctuations in operating results; further impairment of intangible assets; decline in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; number of clinical trials necessary to support an NDA for, and regulatory approval and successful commercialization, of Medidur; development of the Latanoprost Product and any exercise by Pfizer of its option; ability of Tethadur to successfully deliver large biologic molecules and development of products using Tethadur; ability to successfully develop product candidates, complete clinical trials and receive regulatory approvals; ability to market and sell products; success of current and future license agreements; termination of license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. You should read and interpret any forward-looking statements together with these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Follow pSivida on social media:

Twitter: <https://twitter.com/pSividaCorp>

Facebook: <https://www.facebook.com/pages/PSivida-Corp/544893792199562>

LinkedIn: <http://www.linkedin.com/company/psivida>

Google+:
<https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts>

The President's Blog: <http://www.thechairmansblog.com/paul-ashton>

For more information on pSivida, visit www.psivida.com.

In US

Martin E. Janis & Company, Inc.
Beverly Jedynek
President
+1 312 943 1123
M: +1 773 350 5793
bjedynek@janispr.com

[In Australia](#)

Rudi Michelson
Monsoon Communications
03 9620 3333
M: 0411 402 737
rudim@monsooncom.au